Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2016-08-27T04:08:35Z | - |
dc.date.available | 2016-08-27T04:08:35Z | - |
dc.date.issued | 2015 | * |
dc.identifier.issn | 1386-6532 | * |
dc.identifier.issn | 1873-5967 | * |
dc.identifier.other | OAK-16062 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/217854 | - |
dc.description.abstract | Background: The incidence of herpes zoster is substantial during bortezomib treatment in patients with multiple myeloma (MM). Objectives: This study aimed to elucidate the effect of chemotherapy with or without bortezomib in MM patients on their herpes zoster incidence and varicella zoster virus (VZV)-specific cell-mediated immunity (CMI). Study design: Peripheral blood mononuclear cells were collected at baseline and after 1 month of bortezomib-based or thalidomide-based chemotherapy and then analyzed using VZV-specific interferongamma (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay. The clinical data from these patients were analyzed in relation to the ELISPOT results. Results: Of 58 patients analyzed, 39 patients received bortezomib and the other 19 patients, thalidomide. Among them, 5 patients developed herpes zoster during chemotherapy; all 5 were being treated with the bortezomib-based regimen and were not receiving prophylactic anti-viral agents. The median onset of herpes zoster was 32 days (range, 15-95 days) from the initiation of chemotherapy. Among patients who received bortezomib therapy, acyclovir prophylaxis significantly reduced the risk for herpes zoster (100-day cumulative incidence, 0% vs. 49.5%; p < 0.001). Spot-forming cell (SFC) counts in the IFN-gamma ELISPOT assay decreased from baseline after bortezomib (p = 0.011) or thalidomide (p = 0.096) treatment. Patients with baseline SFCs greater than 20/10(6) mononuclear cells exhibited significantly higher incidence of herpes zoster (100-day cumulative incidence, 34.8% vs. 0%; p = 0.040). Conclusions: Bortezomib treatment significantly reduced VZV-specific CMI, and high baseline SFC counts in patients receiving this treatment without acyclovir prophylaxis were associated with a significantly increased risk for herpes zoster. (C) 2015 Elsevier B.V. All rights reserved. | * |
dc.language | English | * |
dc.publisher | ELSEVIER SCIENCE BV | * |
dc.subject | Varicella-zoster virus | * |
dc.subject | Enzyme-linked immunospot assay | * |
dc.subject | Herpes zoster | * |
dc.subject | Multiple myeloma | * |
dc.subject | Bortezomib | * |
dc.title | Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy | * |
dc.type | Article | * |
dc.relation.volume | 73 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 64 | * |
dc.relation.lastpage | 69 | * |
dc.relation.journaltitle | JOURNAL OF CLINICAL VIROLOGY | * |
dc.identifier.doi | 10.1016/j.jcv.2015.10.018 | * |
dc.identifier.wosid | WOS:000367390700013 | * |
dc.identifier.scopusid | 2-s2.0-84949449433 | * |
dc.author.google | Kim, Ji-Won | * |
dc.author.google | Min, Chang-Ki | * |
dc.author.google | Mun, Yeung-Chul | * |
dc.author.google | Park, Yong | * |
dc.author.google | Kim, Byung Soo | * |
dc.author.google | Nam, Seung-Hyun | * |
dc.author.google | Koh, Youngil | * |
dc.author.google | Kwon, Ji-Hyun | * |
dc.author.google | Choe, Pyoeng Gyun | * |
dc.author.google | Park, Wan Beom | * |
dc.author.google | Kim, Inho | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |